

Cancer

## Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03330990 GO40785  
RXDX-101-14

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03330990 GO40785 RXDX-101-14**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---